{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:03Z","timestamp":1792602903912,"version":"4.5.0"},"reference-count":72,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/17460441.2023.2224555","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T20:57:58Z","timestamp":1687640278000},"page":"835-850","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["New directions in psychiatric drug development: promising therapeutics in the pipeline"],"prefix":"10.1080","volume":"18","author":[{"given":"Linda S.","family":"Brady","sequence":"first","affiliation":[{"name":"Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Lisanby","sequence":"additional","affiliation":[{"name":"Division of Translational Research, National Institute of Mental Health, Bethesda,MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Gordon","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1666102"},{"key":"e_1_3_4_5_1","unstructured":"U.S. Food and Drug Administration Novel Drug Approvals for 2023. Available from: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2023."},{"key":"e_1_3_4_6_1","unstructured":"Breakthrough Therapy Approvals. Available from: fda.gov\/drugs\/nda-and-bla-approvals\/breakthrough-therapy-approvals"},{"key":"e_1_3_4_7_1","unstructured":"Fast Track Approvals. Available from: fda.gov\/drugs\/nda-and-bla-approvals\/fast-track-approvals"},{"key":"e_1_3_4_8_1","unstructured":"U.S. Food and Drug Administration Breakthrough Therapy Approvals. Available from: https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/breakthrough-therapy-approvals"},{"key":"e_1_3_4_9_1","unstructured":"U.S. Food and Drug Administration Fast Track Approvals. Available : fda.gov\/drugs\/nda-and-bla-approvals\/fast-track-approvals"},{"key":"e_1_3_4_10_1","unstructured":"U.S. National Library of Medicine ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1714-9097"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108035"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01560-0"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01580-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-022-00320-1"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14316"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01576-z"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21056"},{"key":"e_1_3_4_20_1","unstructured":"NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality [Apr 1 2023]. Available from: https:\/\/www.prnewswire.com\/news-releases\/nrx-pharmaceuticals-reports-minutes-of-recent-us-food-and-drug-administration-fda-meeting-on-the-development-of-nrx-101-to-treat-severe-bipolar-depression-in-patients-with-suicidality-301744832.html"},{"key":"e_1_3_4_21_1","unstructured":"Biotech F. Biotech pipeline hosts 163 potential meds for mental illness with depression dominating: PhRMA [Apr 1 2023]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/biotech-pipeline-hosts-163-potential-meds-mental-illness-depression-treatments-making"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102568"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008489"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3314"},{"key":"e_1_3_4_25_1","unstructured":"Psychiatric Genomics Consortium [Apr 1 2023]. Available from: https:\/\/pgc.unc.edu\/"},{"key":"e_1_3_4_26_1","unstructured":"CommonMind Consortium Knowledge Portal. Available from: https:\/\/www.synapse.org\/\/#!Synapse:syn2759792\/wiki\/197283"},{"key":"e_1_3_4_27_1","unstructured":"The Schizophrenia Exome Sequencing Meta-analysis (SCHEMA) Consortium. Available from: https:\/\/schema.broadinstitute.org\/about"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04434-5"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00857-4"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0090-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2732"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4051"},{"key":"e_1_3_4_33_1","unstructured":"Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed). Available from: https:\/\/grants.nih.gov\/grants\/guide\/pa-files\/par-20-026.html"},{"key":"e_1_3_4_34_1","unstructured":"Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes. Available from: https:\/\/sspsygene.ucsc.edu\/"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.156166"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060930"},{"key":"e_1_3_4_37_1","unstructured":"Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes (SSPsyGene) Consortium Available from: sspsygene.ucsc.edu"},{"key":"e_1_3_4_38_1","unstructured":"NIH The BRAIN Initiative\u00ae. Available from: https:\/\/braininitiative.nih.gov\/"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac962"},{"key":"e_1_3_4_40_1","unstructured":"PsychENCODE Consortium. Available from: http:\/\/www.psychencode.org\/"},{"key":"e_1_3_4_41_1","article-title":"Cross-ancestry, cell-type-informed atlas of gene, isoform, and splicing regulation in the developing human brain","author":"Wen C","unstructured":"Wen C, Margolis M, Dai R, et al. Cross-ancestry, cell-type-informed atlas of gene, isoform, and splicing regulation in the developing human brain. medRxiv. 2023 Mar 6.","journal-title":"medRxiv"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1909567"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00025-1"},{"key":"e_1_3_4_44_1","unstructured":"DSP-0038 by Sunovion Pharmaceuticals for Alzheimer\u2019s Disease: Likelihood of Approval. Available from: https:\/\/www.pharmaceutical-technology.com\/data-insights\/dsp-0038-sunovion-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval\/"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2022.1985108"},{"key":"e_1_3_4_46_1","volume-title":"Silver Spring (MD): Food and Drug Administration (US)","author":"FDA-NIH Biomarker Working Group","year":"2016","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]: National Center for Biotechnology Information (US), Bethesda (MD). Silver Spring (MD): Food and Drug Administration (US). 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00583-z"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20883"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105121"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00680-z"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13274"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.12.141"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac176"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2196\/37225"},{"key":"e_1_3_4_55_1","unstructured":"Biomarkers Consortium - Remote Digital Monitoring and Patient-Centric Medical Product Development. Available from: https:\/\/fnih.org\/our-programs\/biomarkers-consortium\/digitalmonitoring"},{"key":"e_1_3_4_56_1","unstructured":"U.S. Food and Drug Administration. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. Draft Guidance for Industry Investigators and Other Stakeholders 2021. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations"},{"key":"e_1_3_4_57_1","unstructured":"U.S. Food and Drug Administration. Framework for the Use of DHTs in Drug and Biological Product Development [Apr 1 2023]. Available from: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/digital-health-technologies-dhts-drug-development"},{"key":"e_1_3_4_58_1","unstructured":"BEST Biomarker Category and Examples of Corresponding Drug Development Uses. Available from: https:\/\/www.Fda.gov\/drugs\/biomarker-qualification-program."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2009.11.004"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803161-2.00018-7"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2548"},{"key":"e_1_3_4_62_1","unstructured":"Multimodal Biomarkers for CNS Disorders: Development Integration and Clinical Utility Available from: https:\/\/www.nationalacademies.org\/event\/03-13-2023\/multimodal-biomarkers-for-central-nervous-system-disorders-development-integration-and-clinical-utility-a-workshop"},{"key":"e_1_3_4_63_1","unstructured":"Identification of Concepts and Terminology for Multi-Component Biomarkers Available: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-public-meeting-identification-concepts-and-terminology-multi-component-biomarkers-03232022"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz027"},{"key":"e_1_3_4_65_1","unstructured":"ERP Biomarker Qualification Consortium. Available from: https:\/\/erpbiomarkers.org\/"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.02.018"},{"key":"e_1_3_4_67_1","unstructured":"Accelerating Medicines Partnership\u00ae Schizophrenia. Available from: https:\/\/www.ampscz.org\/"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21038"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.778134"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00332-5"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.4533"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2022.12.004"},{"key":"e_1_3_4_73_1","unstructured":"Developing Tools to Inform Treatment Selection in Depression [Apr 1 2023]. Available from: https:\/\/www.nimh.nih.gov\/funding\/grant-writing-and-application-process\/concept-clearances\/2022\/developing-tools-to-inform-treatment-selection-in-depression"},{"key":"e_1_3_4_74_1","unstructured":"Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3\/UH3 Clinical Trial Optional) [Jun 5 2023]. Available from: https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/RFA-MH-24-120.html"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2023.2224555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T08:42:49Z","timestamp":1711356169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2023.2224555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/17460441.2023.2224555"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2023.2224555","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}